SB-431542

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
SB-431542
SB431542.png
Identifiers
ChEBI CHEBI:91108 YesY
ChEMBL ChEMBL440084
ChemSpider 3716512
8216
Jmol 3D model Interactive image
PubChem 4521392
  • InChI=1S/C22H16N4O3/c23-21(27)13-4-6-14(7-5-13)22-25-19(20(26-22)16-3-1-2-10-24-16)15-8-9-17-18(11-15)29-12-28-17/h1-11H,12H2,(H2,23,27)(H,25,26)
    Key: FHYUGAJXYORMHI-UHFFFAOYSA-N
  • InChI=1/C22H16N4O3/c23-21(27)13-4-6-14(7-5-13)22-25-19(20(26-22)16-3-1-2-10-24-16)15-8-9-17-18(11-15)29-12-28-17/h1-11H,12H2,(H2,23,27)(H,25,26)
    Key: FHYUGAJXYORMHI-UHFFFAOYAN
  • NC(=O)c1ccc(cc1)c2nc(c3ccc4OCOc4c3)c([nH]2)c5ccccn5
Properties
C22H16N4O3
Molar mass 384.4
Vapor pressure {{{value}}}
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

SB-431542 is a drug candidate developed by GlaxoSmithKline (GSK) as an inhibitor of the activin receptor-like kinase (ALK) receptors, ALK5, ALK4 and ALK7.[1] (It is NOT an ALK inhibitor).

In-vitro studies

It also suppressed the TGF-beta-induced proliferation of osteosarcoma cells in humans.[1]

As of January 2016 There are no clinical trials registered for SB-431542 for cancer or any other indication.[2]

In vitro use

The treatment with SB431542 is a robust, clinically applicable, and efficient system for generating mesenchymal stem/stromal cells (MSCs) from human iPSCs.[3]

References

<templatestyles src="Reflist/styles.css" />

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


  1. 1.0 1.1 Lua error in package.lua at line 80: module 'strict' not found.
  2. Search results for SB-431542
  3. Chen Y S, Pelekanos R A., Ellis R L., et al and Nicholas M. Fisk (2012). Small Molecule Mesengenic Induction of Human Induced Pluripotent Stem Cells to Generate Mesenchymal Stem/Stromal Cells Stem Cells Trans Med., 1(2), 83-95 doi:10.5966/sctm.2011-0022